BELLEVUE, WA / ACCESSWIRE / May 10, 2022 / Mr. Kingma will continue to lead and build the company's finance department, as well as oversee the development, growth and strategic direction of EMulate's wholly owned subsidiaries: Cellsana Therapeutics (oncology), Mensana Therapeutics (mental health), Indolor Therapeutics (pain management) and all future subsidiaries in his new role as General Manager, EMulate Subsidiaries.

EMulate Therapeutics is a clinical-stage therapeutic device company utilizing its patented proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE^®), to provide safe and effective therapeutic treatments for numerous unmet medical needs. The company has completed feasibility clinical trials in patients afflicted with glioblastoma and diffuse midline glioma with very encouraging results and is planning pivotal (phase III) trials for each indication in the near future. Recently, the company generated encouraging pre-clinical data in validated pre-clinical pain management and mental health models, and it has demonstrated effects in treating health conditions in animals (pets) and in bioagricultural diseases, as well.

Kyle Kingma has over 15 years of experience in the finance sector with over 10 years as the senior finance professional at EMulate Therapeutics. Kyle is accomplished in leading teams and building systems to guide a company from startup stage through IPO readiness. Kyle has designed, implemented and maintained systems that integrate company goals and objectives into finance, information technology, operations and business development. In his time at EMulate Therapeutics and working with Hapbee Technologies, Inc., he has managed and directed finances for over $80M in funds raised as well as over $5M in non-dilutive financing. In the newly created role as General Manager of EMulate Subsidiaries, Kyle will continue to coordinate outreach to strategic and investment partners in each of EMulate's target sectors, with an initial focus on Cellsana Therapeutics (oncology), Indolor Therapeutics (pain management) and Mensana Therapeutics (mental health). Kyle demonstrated his skill and ability to successfully oversee financial and partnering operations of EMulate's first spin-out company, Hapbee Technologies (HAPB:TSXV). His role in partnering with Hapbee's CFO and leadership team during the formative period of its development was pivotal to the achievement of Hapbee's public listing. Kyle has spearheaded outreach to hundreds of companies, funds and advocacy groups in the past year, which has led to EMulate's first federal grant submission, as well as multiple conversations with potential strategic and funding partners. Kyle began his professional career in the audit practice at KPMG, where he gained wide experience with an array of clients, from startups to multinational public companies.

"I am very excited to announce Kyle's promotion and his expanded role with the company," stated Chris Rivera, EMulate's President, CEO and Chairman. "He has demonstrated leadership, initiative and competency building out our finance department, as well as leading and partnering with the Hapbee team to successfully help build their finance department and accomplish their listing on the TSXV. His role spearheading our wholly owned subsidiaries, Cellsana Therapeutics (oncology), Mensana Therapeutics (mental health), Indolor Therapeutics (pain management), and all future subsidiaries will be critical to our ability to execute our business strategy and successfully develop therapeutic programs for each of these disease specialties."

"In my mind, EMulate is the medical industry's first, true "Digital Therapeutic" platform and technology that can truly benefit disease outcomes. I look forward to leading the development of the Celllsana, Indolor and Mensana pipelines," stated Mr. Kingma. "As with Hapbee Technologies, Inc., our first spin-out company, I see huge potential for EMulate's technology to impact the lives of those who need it most through the further development of our groundbreaking technology."

About EMulate Therapeutics, Inc.
EMulate Therapeutics is a clinical stage company utilizing its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE^®) to provide safe and effective therapeutic benefits specifically targeted at patients' underlying conditions. The company has generated encouraging human data from patients afflicted with glioblastoma and diffuse midline glioma and is preparing for pivotal (phase III) studies in each indication. It has also generated encouraging preclinical data in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health and bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB:TSVX). Hapbee is a commercial stage consumer technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.

Company Contact:
David Matteson
dmatteson@emultatetx.com
Cell: 425/478-2121

Investor Contact
James Carbonara
Hayden IR
Tel (646) 755-7412
james@haydenir.com

SOURCE: EMulate Therapeutics Inc